Gennova Gets DCGI Nod To Conduct Phase 2,3 Trials Of Its MRNA COVID-19 Vaccine


The study will be conducted in India at 10-15 sites in Phase II and 22-27 sites in Phase III. Gennova plans to use the DBT-ICMR clinical trial network sites for the study.

Source

Leave a Comment

Your email address will not be published.